Is The Bloom Off The Rose For Big Pharma And Biosimilars?
Landscape Shifts As Originators Signal Waning Interest In Off-Patent Biologics
After a wave of big pharma interest in the biosimilars arena, originator enthusiasm for the sector appears to be waning – potentially opening up an opportunity for newcomers to compete on off-patent biologics.
